Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Hikma Farmaceutica, (Portugal) S.A.
WARNING LETTER
•Hikma Farmaceutica, (Portugal) S.A.•March 28, 2014

Hikma Farmaceutica, (Portugal) S.A. – FDA Warning Letter, Mar 28, 2014

Record Details

The FDA issued a Warning Letter to Hikma Farmaceutica, (Portugal) S.A. following a March 20-28, 2014 inspection, identifying significant violations of CGMP regulations (21 CFR Parts 210 and 211), rendering their drug products adulterated. The firm's April 16, 2014 response and subsequent correspondences were deemed insufficient.

Key violations include: 1. **Failure to thoroughly investigate discrepancies (21 CFR 211.192):** The firm failed to adequately investigate 23 environmental monitoring (EM) excursions in Class 100 aseptic areas from January 2012 to December 2013. Investigations cited "possible root causes" like mishandling/poor aseptic technique but couldn't determine actual root causes, disregarding excursions without justification and failing to assess product impact. The proposed corrective action of improving EM plate preparation was rejected as unsupported. Concerns were raised about pre-incubation of EM media plates potentially compromising growth promotion. This is a repeat violation from 2004, 2007, and 2011 inspections. 2. **Inadequate written procedures for production and process control (21 CFR 211.100(a)):** The firm failed to provide adequate challenge test vials for qualifying operators and QA staff for visual inspection. 14 of

Company
Hikma Farmaceutica, (Portugal) S.A.
Inspection date
March 28, 2014
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Maan Abduldayem (Consumer safety Officer )
  • Riad Ali Mechlaoui
  • Thomas J. Cosgrove
View Company Profile

ID · 1a434d31-fc9b-40cf-b817-dd4d3436ca9c

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.100(a)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 356C(a)(1)

Full citation text and observation details available on the Dashboard.

Other documents for Hikma Farmaceutica, (Portugal) S.A.
  • 483 - 2023-04-21April 21, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hikma Farmaceutica, (Portugal) S.A.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.